This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Rheumatic mitral valve diseases류마티스 승모판질환

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I05 (Rheumatic mitral valve diseases)  |  Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsRheumatic mitral stenosis (I05.0), rheumatic mitral regurgitation (I05.1), rheumatic mitral stenosis with regurgitation (I05.2), bileaflet mitral stenosis
C. Adult onsetRheumatic mitral stenosis forms over decades after childhood rheumatic fever and usually becomes symptomatic in the 30s to 50s. In developed countries where the incidence of rheumatic fever has declined, onset after the 60s is more common.
1. HistoryStenosis described by Riviere in 1770. Commissurotomy proposed by Brunton in 1902. First mitral commissurotomy performed by Cutler in 1923 and Souttar in 1925. Inoue balloon valvuloplasty introduced in 1984.
2. CausesNearly all mitral stenosis is due to rheumatic heart disease. Repeated endocarditis causes leaflet thickening, adhesion, and calcification, and chordal fusion and shortening, reducing the valve orifice area.
3. GeneticsInheritance of genetic susceptibility to rheumatic fever (HLA-DR association). There is no independent genetic factor for valve damage itself; immune gene polymorphisms that determine the intensity of the autoimmune reaction are involved.
4. General epidemiologyMitral involvement is the most common in rheumatic heart disease (85–90%). Of the 33.9 million people worldwide with rheumatic heart disease, many have mitral stenosis. Female predominance (about 2:1). High burden in low- and middle-income countries.
5. PathophysiologyRepeated rheumatic endocarditis → leaflet fibrosis, thickening, and commissural fusion → reduced valve orifice area → increased left atrial pressure → pulmonary hypertension. Chordal adhesion also contributes to regurgitation.
6. SymptomsExertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, palpitations (atrial fibrillation), hemoptysis (pulmonary venous hypertension), thromboembolism (stroke), fatigue.
7. SignsMitral opening snap, low-pitched diastolic murmur in the mitral area (Duroziez murmur), presystolic accentuation. Mitral flush of the cheeks. Accentuated P2 with pulmonary hypertension.
8. ScreeningEchocardiography used to screen asymptomatic patients for rheumatic heart disease in high-risk regions. Echocardiographic measurement of mitral valve area (MVA) is key. WHO 2024: handheld ultrasound recommended as first choice.
9. DiagnosisEchocardiography: valve area (pressure half-time method, planimetry), Wilkins score, pulmonary artery pressure. ECG: left atrial enlargement (P mitrale), atrial fibrillation. Pressure gradient measured by cardiac catheterization.
10. TreatmentMVA ≤1.5cm² + symptomatic: percutaneous balloon mitral valvuloplasty (PBMV) or surgical commissurotomy. Anticoagulation for atrial fibrillation, diuretics. Valve repair or replacement for severe regurgitation.
11. PrognosisDecades elapse from the asymptomatic to the symptomatic phase. Onset of atrial fibrillation is the turning point for worsening prognosis. 5-year event-free survival after PBMV 80–90%. 10-year survival after valve replacement about 70–80%.
12. PreventionPreventing rheumatic recurrence and accumulation of valve damage with secondary prophylaxis (regular benzathine penicillin G) is key. Maintain anticoagulation to prevent atrial fibrillation-related embolism.
13. References2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease … and 9 other papers

1. History

The history of rheumatic mitral valve disease, especially mitral stenosis, dates back to the 18th century. In 1770, Raymond Vieussens of England described the association between atrial enlargement and mitral valve deformity, and in 1785 William Withering reported symptom relief using digitalis. In the 19th century, Jean-Nicolas Corvisart and René Laennec described the characteristic murmur of mitral stenosis through auscultation and linked it to pathological findings.

In the early 20th century, attempts at surgical treatment began. In 1902, Lauder Brunton of England first proposed mitral stenosis as a disease that 'should be cut open,' but this was not realized because of the limitations of surgical techniques at the time. In 1923, Elliott Cutler and Claude Beck of the United States attempted the first open-heart operation, but the patient died; in 1925, Henry Souttar of England performed the first successful mitral commissurotomy by separating the fused commissures with a finger through the left atrial appendage. Thereafter, in the 1940s and 1950s, Harken, Bailey, and others systematized and performed this procedure.

In the 1950s, the clinical application of cardiopulmonary bypass made direct commissurotomy possible, and in the 1960s, with the introduction of prosthetic heart valves, valve replacement became established as one of the standard treatments. The development of bioprosthetic and mechanical valves and the optimization of anticoagulation therapy were the major advances of this period.

In 1984, Kaoru Inoue of Japan developed percutaneous balloon mitral valvuloplasty (PBMV), opening an era in which the commissures are separated with a balloon catheter without thoracotomy. The Inoue balloon technique subsequently spread worldwide and is currently recommended as first-line treatment for patients with mitral stenosis who have suitable anatomy. Advances in echocardiography (especially Doppler echocardiography) have made it possible to measure valve area and pressure gradient accurately and noninvasively, and valve morphology assessment systems such as the Wilkins score have been developed and are used to assess suitability for PBMV.


2. Causes

The cause of rheumatic mitral valve disease is almost entirely repeated endocarditis due to rheumatic fever. Rheumatic endocarditis forms small verrucous thrombi along the valve closure line, and as these heal, fibrosis and scarring accumulate in the valve tissue. As this process repeats over years to decades, the leaflets become thickened and stiff, the commissures fuse, and the chordae tendineae become thickened, shortened, and fused.

Rare non-rheumatic causes of mitral stenosis include congenital mitral anomalies (congenital commissural fusion), valve obstruction effect by left atrial myxoma, carcinoid heart disease, drug-induced causes (ergotamine, methysergide), radiation heart disease, and lupus endocarditis. However, none of these is nearly as common as the rheumatic cause.

Mitral regurgitation can have both rheumatic and non-rheumatic causes (mitral valve prolapse, ischemic mitral regurgitation, destruction by infective endocarditis, mitral annular calcification, etc.). In rheumatic mitral regurgitation, fibrous thickening of the leaflets, chordal shortening, and annular dilatation contribute in combination. Coexisting rheumatic stenosis and regurgitation (I05.2) is also common, in which case hemodynamic assessment and treatment decisions become more complex.


3. Genetics

The genetic basis of rheumatic mitral valve disease is fundamentally the same as the genetic determinants of host susceptibility to rheumatic fever. As described above, specific alleles of HLA class II genes (especially HLA-DR7, HLA-DRB1*04, etc.) are associated with the risk of rheumatic fever and rheumatic heart disease. The rate of progression and final severity of valve damage also depend on the intensity of the immunological response, which is partly genetically determined.

There are study results indicating that TNF-α promoter polymorphisms, IL-4 receptor gene polymorphisms, and specific single nucleotide polymorphisms (SNPs) of the CTLA-4 gene are associated with the severity of rheumatic heart disease. It has also been hypothesized that polymorphisms of collagen-related genes (COL1A1, COL3A1) affect the intensity of the fibrotic response and are involved in the rate of valve sclerosis.

In twin studies, the correlation in the occurrence and severity of rheumatic heart disease is higher between monozygotic than dizygotic twins, confirming a genetic predisposition, but environmental exposure (opportunities for GAS infection, level of hygiene) also plays a large role. To date, no single gene that independently determines the rate of progression of mitral stenosis has been identified, and polygenic inheritance applies. Genetic testing is not currently used routinely in clinical practice.


4. General epidemiology

Mitral involvement is the most common in rheumatic heart disease, occurring in 85–90% of all patients with rheumatic heart disease. Of these, about 25% have isolated mitral stenosis, 40% combined mitral stenosis and regurgitation, and the remainder isolated regurgitation or combined involvement with other valves. Considering the prevalent population of rheumatic heart disease worldwide (about 33.9 million), the number of patients with rheumatic mitral stenosis reaches tens of millions.

Regarding age of onset, rheumatic fever occurs mainly in childhood (5–15 years), after which valve stenosis progresses over 20–30 years, so symptom onset is concentrated in the 30s to 50s. In developed countries, because the incidence of rheumatic fever is low, diagnosis at older ages is more common. It occurs more than twice as often in women as in men, and during pregnancy the increase in cardiac output can cause rapid worsening of symptoms, leading to obstetric emergencies.

In low- and middle-income countries, rheumatic mitral stenosis still acts as a major cause of heart failure and death at a young age. The World Health Organization (WHO) and the World Heart Federation (WHF) present strengthening of secondary prophylaxis programs and improved access to balloon valvuloplasty in high-burden regions as priorities. In Korea, the prevalence of rheumatic mitral stenosis has been steadily decreasing owing to the decline in the incidence of rheumatic fever, but differentiation from non-rheumatic valvular disease in elderly patients is a clinical challenge.


5. Pathophysiology

The pathophysiology of rheumatic mitral stenosis is the accumulation of structural valve deformity due to repeated rheumatic endocarditis. With each episode of acute rheumatic fever, platelet–fibrin thrombi are deposited on the valve closure line, and as these heal, fibrotic scars form on the leaflets. As recurrences repeat, this process accumulates, and ① thickening and stiffening of the leaflets, ② fibrous fusion of the anteroposterior commissures, ③ thickening, shortening, and fusion of the chordae, and ④ adhesion of the subvalvular apparatus progress.

As the valve orifice area decreases, blood flow from the left atrium to the left ventricle is restricted and left atrial pressure rises. This leads in sequence to increased pulmonary venous pressure, pulmonary edema, and pulmonary hypertension. When pulmonary hypertension becomes chronic, right ventricular hypertrophy and ultimately right heart failure develop. Increased left atrial pressure and atrial dilatation induce atrial fibrillation, and atrial fibrillation increases thrombus formation in the left atrium (especially in the left atrial appendage), raising the risk of systemic embolism.

The normal mitral valve orifice area is 4–6cm²; symptoms begin to appear when the area decreases to 2cm² or less, overt symptoms on exertion appear with moderate stenosis of 1.5cm² or less, and symptoms at rest appear with severe stenosis of 1.0cm² or less. Symptoms may worsen suddenly in situations that increase cardiac output, such as pregnancy, onset of atrial fibrillation, or infection.


6. Symptoms

The main symptoms of rheumatic mitral stenosis are respiratory symptoms due to pulmonary venous hypertension and pulmonary edema. Exertional dyspnea appears first and gradually progresses to orthopnea and paroxysmal nocturnal dyspnea. With severe pulmonary venous hypertension, hemoptysis may occur, which in some cases is due to rupture of pulmonary veins or pulmonary infarction.

Atrial fibrillation commonly occurs as a result of left atrial dilatation and causes sudden palpitations together with rapid worsening of symptoms. The increased heart rate shortens diastolic filling time, raising the transvalvular pressure gradient and worsening pulmonary edema. In atrial fibrillation, the risk of thromboembolism (stroke, peripheral arterial embolism) due to thrombus formation in the left atrial appendage increases greatly.

Fatigue and reduced exercise tolerance are also common symptoms, due to reduced cardiac output. When right heart failure has progressed, jugular venous distension, hepatic congestion (right upper quadrant pain, anorexia), ascites, and lower extremity edema accompany it. Diastolic angina (exertional angina) is also reported in some patients, caused by increased right ventricular strain due to pulmonary hypertension and reduced coronary blood flow due to impaired left ventricular filling.


7. Signs

The typical auscultatory findings of rheumatic mitral stenosis are ① mitral opening snap (OS), ② low-pitched diastolic murmur (diastolic rumble) in the mitral area, and ③ presystolic accentuation in sinus rhythm. The opening snap is a high-pitched click heard 0.04–0.12 seconds after the second heart sound (S2), and a shorter A2-OS interval suggests more severe stenosis. The diastolic murmur is best heard at the apex and becomes more prominent in the left lateral decubitus position and after light exercise.

The first heart sound (S1) may be accentuated (crisp S1), because the valve closes forcefully while the leaflets are still mobile. With severe calcification or fibrosis of the valve, S1 becomes soft. When pulmonary hypertension is present, P2 accentuation and the Graham Steell murmur (pulmonary regurgitation murmur) are observed. Signs of right heart failure include jugular venous distension, hepatomegaly, hepatojugular reflux, and lower extremity edema. 'Mitral flush' is a bluish-purple flush on the cheeks of patients with typical rheumatic mitral stenosis, resulting from peripheral vasoconstriction due to pulmonary hypertension.


8. Screening

Screening for rheumatic mitral valve disease takes place in two contexts: detection of asymptomatic rheumatic heart disease in regions at high risk for rheumatic fever, and regular follow-up of patients with known rheumatic heart disease. The WHO 2024 guideline recommends echocardiographic screening of school-age children and adolescents in high-prevalence regions as the core of the primary prevention strategy.

Transthoracic echocardiography (TTE) is the standard primary screening tool, assessing mitral valve area (MVA), leaflet morphology and mobility, Doppler pressure gradient, left atrial size, and pulmonary artery pressure. In resource-limited settings, handheld echocardiography (point-of-care ultrasound) shows a much higher detection rate than auscultation and is actively recommended by WHO. In patients with established heart disease, regular echocardiographic follow-up at intervals of 6 months to 2 years is recommended, with the interval adjusted according to the severity of stenosis.

Immediate echocardiographic reassessment is needed upon onset of atrial fibrillation, sudden worsening of symptoms, or when pregnancy is planned. Exercise stress echocardiography is useful when resting echocardiographic results and symptoms do not match. Cardiac catheterization is performed when echocardiographic results are uncertain or coexisting coronary artery disease is suspected.


9. Diagnosis

Echocardiography is the key tool for diagnosis and severity assessment. On two-dimensional echocardiography, doming of the anterior mitral leaflet, anterior motion of the posterior leaflet, leaflet thickening, and commissural fusion are typical findings. Mitral valve area is measured by the pressure half-time method (PHT: MVA = 220/PHT) and direct planimetry. Doppler examination measures the mean mitral gradient, and ≥10mmHg suggests severe stenosis.

The Wilkins score is a tool that scores leaflet mobility, thickening, calcification, and subvalvular thickening at 1–4 points each; a total score of ≤8 indicates anatomy suitable for PBMV. Transesophageal echocardiography (TEE) is essential for checking for left atrial appendage thrombus and for real-time guidance during PBMV.

On the electrocardiogram, P-wave abnormalities (left atrial enlargement, abnormal P wave = P mitrale), findings of right ventricular hypertrophy, and atrial fibrillation are observed. Chest X-ray shows left atrial enlargement (posterior displacement of the esophagus, double density at the left heart border), pulmonary venous congestion, Kerley B lines, and findings of pulmonary hypertension. Cardiac CT and MRI are used adjunctively for detailed anatomical assessment and for differentiating causes of heart failure.


10. Treatment

Treatment decisions for rheumatic mitral stenosis are based on symptoms, valve area, anatomical characteristics, and associated complications (atrial fibrillation, thrombus, pulmonary hypertension). When there are no symptoms and MVA >1.5cm², medical therapy and regular follow-up are the rule. When symptoms are present (NYHA II or higher) or MVA ≤1.5cm², interventional treatment is considered.

Percutaneous balloon mitral valvuloplasty (PBMV) is recommended as first-line treatment in anatomically suitable patients (Wilkins score ≤8, no severe mitral regurgitation, no left atrial appendage thrombus) (Class I, Level B-NR). When left atrial appendage thrombus is present, reassessment after anticoagulation or surgical treatment is chosen. PBMV is an effective procedure that separates the commissures by balloon dilation, immediately increasing MVA.

In patients anatomically unsuitable for PBMV (severe calcification, high Wilkins score, coexisting severe regurgitation), surgical mitral commissurotomy or mitral valve replacement (MVR) is performed. Medical therapy includes diuretics (relief of pulmonary venous congestion), beta-blockers or non-dihydropyridine calcium channel blockers (heart rate control), and anticoagulants (warfarin for atrial fibrillation or left atrial appendage thrombus, maintaining INR 2.0–3.0). Current guidelines on prevention of infective endocarditis do not recommend routine prophylactic antibiotics in rheumatic mitral valve disease, but risk assessment before procedures is needed.


11. Prognosis

The natural history of rheumatic mitral stenosis is gradual worsening over decades. Even if the asymptomatic period is long, the disease tends to progress rapidly once symptoms appear, and 10-year survival without treatment after diagnosis is about 50–60%. Atrial fibrillation, pulmonary hypertension, and thromboembolism greatly worsen the prognosis. In particular, onset of atrial fibrillation is the turning point for worsening prognosis, after which the risks of stroke and heart failure rise sharply.

When PBMV is successful (MVA >1.5cm², no mitral regurgitation), 5-year event-free survival reaches 80–90%, and 10-year survival is also excellent. However, when valve anatomy is unfavorable or restenosis occurs, repeat PBMV or surgical treatment is needed. Ten-year survival after surgical valve replacement is about 70–80% with mechanical valves, and appropriate anticoagulation management is essential. Rheumatic mitral stenosis during pregnancy increases the risk of maternal heart failure and perinatal complications, so optimizing cardiac status before pregnancy is important.


12. Prevention

Prevention of rheumatic mitral valve disease follows the same principles as prevention of rheumatic fever. Primary prevention blocks the development of rheumatic fever itself through early diagnosis and adequate antibiotic treatment of GAS pharyngitis (10-day penicillin course). Secondary prevention prevents recurrence in patients who already have rheumatic fever or rheumatic heart disease through regular administration of benzathine penicillin G (intramuscular every 3–4 weeks), and this is the most powerful means of preventing accumulation of valve damage.

The duration of secondary prophylaxis is at least 10 years or until age 40 when carditis is present, and lifelong administration is considered when residual valve lesions are present. Community-based RHD control programs to improve adherence to secondary prophylaxis are being implemented in low- and middle-income countries. Secondary prophylaxis should be continued even after valve intervention (PBMV or surgery). In patients with atrial fibrillation, warfarin-based anticoagulation is the key treatment for preventing thromboembolism (stroke).


13. References

  1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American College of Cardiology. 2021;77(4):e25-e197. DOI: 10.1016/j.jacc.2020.11.018. PMID: 33342586.

  2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632. DOI: 10.1093/eurheartj/ehab395. PMID: 34453165.

  3. Inoue K, Owaki T, Nakamura T, et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. Journal of Thoracic and Cardiovascular Surgery. 1984;87(3):394-402. PMID: 6700243.

  4. Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. British Heart Journal. 1988;60(4):299-308. DOI: 10.1136/hrt.60.4.299. PMID: 3190958.

  5. Carabello BA. Modern management of mitral stenosis. Circulation. 2005;112(3):432-437. DOI: 10.1161/CIRCULATIONAHA.104.532382. PMID: 16027271.

  6. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.

  7. Remenyi B, Carapetis J, Wyber R, et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nature Reviews Cardiology. 2013;10(5):284-292. DOI: 10.1038/nrcardio.2013.34. PMID: 23459592.

  8. Manjunath CN, Srinivas P, Ravindranath KS, Dhanalakshmi C. Incidence and patterns of valvular heart disease in a tertiary care high-volume cardiac center. Journal of Heart Valve Disease. 2014;23(3):312-320. PMID: 25296444.

  9. Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet. 2009;374(9697):1271-1283. DOI: 10.1016/S0140-6736(09)60994-6. PMID: 19747723.

  10. Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. New England Journal of Medicine. 2007;357(5):470-476. DOI: 10.1056/NEJMoa065085. PMID: 17671255.